相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts
Jacqueline A. Shaw et al.
CLINICAL CANCER RESEARCH (2017)
Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer
Karen Page et al.
CLINICAL CHEMISTRY (2017)
Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma
John B. McIntyre et al.
HISTOPATHOLOGY (2017)
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2016)
ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients
David Chu et al.
CLINICAL CANCER RESEARCH (2016)
ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action
Guowei Gu et al.
CLINICAL CANCER RESEARCH (2016)
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
Peilu Wang et al.
CLINICAL CANCER RESEARCH (2016)
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers
D. Fumagalli et al.
ANNALS OF ONCOLOGY (2016)
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling
Luca Gelsomino et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
Hazel M. Weir et al.
CANCER RESEARCH (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Charlotte Fribbens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance
Costanza Paoletti et al.
MOLECULAR ONCOLOGY (2016)
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital
Aditya Bardia et al.
ONCOLOGIST (2016)
Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer
Sarah Hrebien et al.
PLOS ONE (2016)
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M. Spoerke et al.
NATURE COMMUNICATIONS (2016)
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
Christopher A. Miller et al.
Nature Communications (2016)
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
Florian Clatot et al.
ONCOTARGET (2016)
Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
Takashi Takeshita et al.
ONCOTARGET (2016)
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Celine Lefebvre et al.
PLOS MEDICINE (2016)
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER plus breast cancer
James D. Joseph et al.
ELIFE (2016)
ESR1 Mutations in Cell-Free DNA of Breast Cancer Predictive Tip of the Iceberg
Suzanne A. W. Fuqua et al.
JAMA ONCOLOGY (2016)
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial
Sarat Chandarlapaty et al.
JAMA ONCOLOGY (2016)
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
Suzanne E. Wardell et al.
CLINICAL CANCER RESEARCH (2015)
Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer
David S. Guttery et al.
CLINICAL CHEMISTRY (2015)
A multiplex allele-specific real-time PCR assay for screening of ESR1 mutations in metastatic breast cancer
Ting Wang et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2015)
Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer
David Sefrioui et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer
Rinath Jeselsohn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Isaac Garcia-Murillas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
Gaia Schiavon et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens
Takashi Takeshita et al.
TRANSLATIONAL RESEARCH (2015)
Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
Jiaxin Niu et al.
ONCOTARGETS AND THERAPY (2015)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2014)
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
L. De Mattos-Arruda et al.
ANNALS OF ONCOLOGY (2014)
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
M. Piccart et al.
ANNALS OF ONCOLOGY (2014)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F. Cardoso et al.
BREAST (2014)
Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor-Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action
Stefan Glueck
CLINICAL BREAST CANCER (2014)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
Rinath Jeselsohn et al.
CLINICAL CANCER RESEARCH (2014)
Editorial: Estrogen Receptor Mutations in Breast Cancer-An Anticipated Rediscovery?
Vincent Giguere
MOLECULAR ENDOCRINOLOGY (2014)
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Min Yu et al.
SCIENCE (2014)
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers
Jamunarani Veeraraghavan et al.
NATURE COMMUNICATIONS (2014)
D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
Keren Merenbakh-Lamin et al.
CANCER RESEARCH (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
The search for ESR1 mutations in breast cancer
Steffi Oesterreich et al.
NATURE GENETICS (2013)
ESR1 Amplification in Breast Cancer by Optimized RNase FISH: Frequent but Low-Level and Heterogeneous
Cathy B. Moelans et al.
PLOS ONE (2013)
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
Shunqiang Li et al.
CELL REPORTS (2013)
Leptin Mediates Tumor-Stromal Interactions That Promote the Invasive Growth of Breast Cancer Cells
Ines Barone et al.
CANCER RESEARCH (2012)
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
Thomas Bachelot et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The landscape of cancer genes and mutational processes in breast cancer
Philip J. Stephens et al.
NATURE (2012)
Sequence analysis of mutations and translocations across breast cancer subtypes
Shantanu Banerji et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer
Kirsten Vang Nielsen et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
A hypersensitive estrogen receptor α mutation that alters dynamic protein interactions
Matthew H. Herynk et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305
Cinzia Giordano et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Estrogen Receptor Mutations and Changes in Downstream Gene Expression and Signaling
Ines Barone et al.
CLINICAL CANCER RESEARCH (2010)
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer
H. Aguilar et al.
ONCOGENE (2010)
Phosphorylation of the mutant K303R estrogen receptor α at serine 305 affects aromatase inhibitor sensitivity
I. Barone et al.
ONCOGENE (2010)
Expression of the K303R Estrogen Receptor-α Breast Cancer Mutation Induces Resistance to an Aromatase Inhibitor via Addiction to the PI3K/Akt Kinase Pathway
Ines Barone et al.
CANCER RESEARCH (2009)
Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients
Saori Tomita et al.
CANCER SCIENCE (2009)
ESR1 gene amplification in breast cancer:: a common phenomenon?
Lindsay A. Brown et al.
NATURE GENETICS (2008)
New experimental models for aromatase inhibitor resistance
Shiuan Chen et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2007)
Association between the estrogen receptor α A908G mutation and outcomes in invasive breast cancer
Matthew H. Herynk et al.
CLINICAL CANCER RESEARCH (2007)
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
Frederik Holst et al.
NATURE GENETICS (2007)
Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation
Kathleen Conway et al.
BREAST CANCER RESEARCH (2007)
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant
Meiyun Fan et al.
CANCER RESEARCH (2006)
Changes in oestrogen receptor-α and -β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells
L. E. Shaw et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2006)
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor
JM Knowlden et al.
ENDOCRINOLOGY (2005)
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer
B Weigelt et al.
CANCER RESEARCH (2005)
Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity
RJ Santen et al.
ENDOCRINE-RELATED CANCER (2005)
Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment
RJ Santen et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance
SRD Johnston et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
MC Gutierrez et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study
K Conway et al.
BREAST CANCER RESEARCH (2005)
Phosphorylation of estrogen receptor a blocks its acetylation and regulates estrogen sensitivity
Y Cui et al.
CANCER RESEARCH (2004)
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model
D Jelovac et al.
CLINICAL CANCER RESEARCH (2004)
Estrogen receptor α (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast
CL Tebbit et al.
GENES CHROMOSOMES & CANCER (2004)
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells
JM Knowlden et al.
ENDOCRINOLOGY (2003)
A molecular signature of metastasis in primary solid tumors
S Ramaswamy et al.
NATURE GENETICS (2003)
The role of estrogen receptors in breast cancer metastasis
SAW Fuqua
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2001)
Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351
AS Levenson et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2001)
分享论文
